New book by Larry Connors Click here Improve your trading - See how
Roche Molecular Diagnostics (SIX: RO, ROG; OTCQX: RHHBY | Quote | Chart | News | PowerRating) announced today the availability of the cobas p 630 Instrument with CE Mark and the AMPLILINK 3.3 Series Software. The cobas p 630 Instrument and the AMPLILINK 3.3 Series Software is intended for the EU and countries outside the United States that accept products with the CE Mark. With this introduction, Roche has the only pre-analytical instrument that unites primary tube handling with fully automated sample preparation, amplification and detection for molecular diagnostics. The AMPLILINK 3.3 Series Software is the latest version of the widely adopted software that integrates the cobas p 630 Instrument with the market leading COBAS(R) AmpliPrep Instruments and COBAS(R) TaqMan(R) Analyzers.
Jeff Heimburger, International Business Leader of Virology at Roche Molecular Diagnostics said, "The complete system provides our customers in the EU and countries outside the US that accept CE Marked products with a flexible and integrated solution with automated pre-analytics and real-time PCR diagnostic testing for a broad menu of important molecular tests (HIV, HCV, and HBV)."
The cobas p 630 Instrument provides a state-of-the art, automated pre-analytical solution for primary tube handling and features full sample traceability and process surveillance. These features effectively eliminate manual steps, pipetting errors, and the associated risks of repetitive stress injuries.
"We are excited by the addition of the cobas p 630 Instrument to our portfolio. Combined with AMPLILINK 3.3 Series Software, the cobas p 630 Instrument specifically addresses the throughput needs of a key customer segment while at the same time reduces hands-on time, a critical measure for lab efficiency" said Neil Gunn, Head of Global Business at Roche Molecular Diagnostics.
About the cobas p 630 Instrument and AMPLILINK 3.3 Series Software
The Roche cobas p 630 Instrument is an automated pre-analytical instrument for primary tube handling. The automation features include: de-capping and capping of the sample tube; pipetting Roche controls from control tubes to sample tubes; pipetting samples from primary tubes to multiple sample tubes. The cobas p 630 Instrument is compatible with a variety of standard primary tubes. Bar-code tracking from primary tube to result ensures full sample traceability. Maximum sample throughput is 154 samples per hour.
The AMPLILINK Software, a Windows(R)-based application, is designed to deliver maximum flexibility, efficiency, and integrity to the laboratory's workflow - from sample input through results output. AMPLILINK 3.3 Series Software manages the operation of the connected COBAS(R) Instruments and Analyzers. One AMPLILINK data station is capable of supporting up to 3 COBAS(R) AmpliPrep Instruments and 3 Analyzers (combination of COBAS(R) AMPLICOR(R), COBAS(R) TaqMan(R) and COBAS(R) TaqMan(R) 48 Analyzers), together with the cobas p 630 Instrument for pre-analytics.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact:
Jessica Brillant
Roche Molecular Diagnostics
Pleasanton, CA
Office: +1-925-730-8503
Mobile: +1-925-980-0260
Jessica.brillant@roche.com
Rick Roose
Roche Molecular Diagnostics
Pleasanton, CA
Office: +1-925-730-8415
Mobile: +1-925-819-0609
Rick.roose@roche.com
Jessica Brillant, +1-925-730-8503, Mobile, +1-925-980-0260, Jessica.brillant@roche.com; or Rick Roose, +1-925-730-8415, Mobile, +1-925-819-0609, Rick.roose@roche.com, both of Roche Molecular Diagnostics
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.